PLYX Initiates Coverage On by Lucid Capital Markets -- Rating Set to Buy
Lucid Capital Markets has initiated coverage on Polaryx Therapeutics (PLYX) with a "Buy" rating and a $7.00 price target. This follows similar positive ratings from other analysts, indicating growing confidence in the company, which focuses on rare pediatric lysosomal storage disorders. Despite a low …